Last updated on July 2019

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections


Brief description of study

The purpose of this study is to compare safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those nAMD patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.

Clinical Study Identifier: NCT03710564

Find a site near you

Start Over

Novartis Investigative Site

Phoenix, AZ United States
  Connect »

Novartis Investigative Site

Beverly Hills, CA United States
  Connect »

Novartis Investigative Site

Huntington Beach, CA United States
  Connect »

Novartis Investigative Site

Mountain View, CA United States
  Connect »

Novartis Investigative Site

Oakland, CA United States
  Connect »

Novartis Investigative Site

Redlands, CA United States
  Connect »

Novartis Investigative Site

Sacramento, CA United States
  Connect »

Novartis Investigative Site

San Francisco, CA United States
  Connect »

Novartis Investigative Site

Santa Barbara, CA United States
  Connect »

Novartis Investigative Site

Colorado Springs, CO United States
  Connect »

Novartis Investigative Site

Deerfield Beach, FL United States
  Connect »

Novartis Investigative Site

Fort Lauderdale, FL United States
  Connect »

Novartis Investigative Site

Fort Myers, FL United States
  Connect »

Novartis Investigative Site

Mount Dora, FL United States
  Connect »

Novartis Investigative Site

Pensacola, FL United States
  Connect »

Novartis Investigative Site

Saint Petersburg, FL United States
  Connect »

Novartis Investigative Site

Marietta, GA United States
  Connect »

Novartis Investigative Site

Wheaton, IL United States
  Connect »

Novartis Investigative Site

West Des Moines, IA United States
  Connect »

Novartis Investigative Site

Shawnee Mission, KS United States
  Connect »

Novartis Investigative Site

Paducah, KY United States
  Connect »

Novartis Investigative Site

New Orleans, LA United States
  Connect »

Novartis Investigative Site

West Monroe, LA United States
  Connect »

Novartis Investigative Site

Waldorf, MD United States
  Connect »

Novartis Investigative Site

Springfield, MA United States
  Connect »

Novartis Investigative Site

Royal Oak, MI United States
  Connect »

Novartis Investigative Site

Las Vegas, NV United States
  Connect »

Novartis Investigative Site

Bloomfield, NJ United States
  Connect »

Novartis Investigative Site

Toms River, NJ United States
  Connect »

Novartis Investigative Site

Syracuse, NY United States
  Connect »

Novartis Investigative Site

Charlotte, NC United States
  Connect »

Novartis Investigative Site

Cleveland, OH United States
  Connect »

Novartis Investigative Site

Fairfield, OH United States
  Connect »

Novartis Investigative Site

Kingston, PA United States
  Connect »

Novartis Investigative Site

Germantown, TN United States
  Connect »

Novartis Investigative Site

Abilene, TX United States
  Connect »

Novartis Investigative Site

Fort Worth, TX United States
  Connect »

Novartis Investigative Site

Harlingen, TX United States
  Connect »

Novartis Investigative Site

Houston, TX United States
  Connect »

Novartis Investigative Site

San Antonio, TX United States
  Connect »

Novartis Investigative Site

Spokane, WA United States
  Connect »

Novartis Investigative Site

Fairfax, VA United States
  Connect »

Novartis Investigative Site

Palo Alto, CA United States
  Connect »

Novartis Investigative Site

Saint Louis, MO United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.